Full Text Journal Articles by
Author Ray D Page

Advertisement

Find full text journal articles








A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial.

David R Spigel, Dianna L Shipley, David M Waterhouse, Suzanne F Jones, Patrick J Ward, Kent C Shih, Brian Hemphill, Michael McCleod, Robert C Whorf, Ray D Page, Joseph Stilwill, Tarek Mekhail, Cindy Jacobs, Howard A Burris, John D Hainsworth,

BACKGROUND:This randomized, double-blinded, phase II trial evaluated the efficacy of carboplatin and pemetrexed plus either apatorsen, an antisense oligonucleotide targeting heat shock protein (Hsp) 27 mRNA, or placebo in patients with previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC). METHODS:Patients were randomized 1:1 to Arm A (carboplatin/pemetrexed plus apatorsen) ... Read more >>

Oncologist (The oncologist)
[2019, :]

Cited: 0 times

View full text PDF listing >>



Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer.

Natasha B Leighl, Ray D Page, Victoria M Raymond, Davey B Daniel, Stephen G Divers, Karen L Reckamp, Miguel A Villalona-Calero, Daniel Dix, Justin I Odegaard, Richard B Lanman, Vassiliki A Papadimitrakopoulou,

PURPOSE:Complete and timely tissue genotyping is challenging, leading to significant numbers of patients with newly diagnosed metastatic non-small cell lung cancer (mNSCLC) being undergenotyped for all eight genomic biomarkers recommended by professional guidelines. We aimed to demonstrate noninferiority of comprehensive cell-free DNA (cfDNA) relative to physician discretion standard-of-care (SOC) tissue ... Read more >>

Clin. Cancer Res. (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2019, 25(15):4691-4700]

Cited: 3 times

View full text PDF listing >>



Advertisement

Implementing an Electronic End-of-Life Chemotherapy Utilization Measure.

Joshua Kraut, Kathi Mooney, John W Sweetenham, Ray D Page, Kerin Adelson, Vineeta Agarwala, Kristen L Fessele, H James Hamrick, Irene Kaganman, James Martineau, Amy P Abernethy, Neal J Meropol,

J Oncol Pract (Journal of oncology practice)
[2019, 15(4):220-223]

Cited: 0 times

View full text PDF listing >>



Reducing Cancer Costs Through Symptom Management and Triage Pathways.

Ronald Barkley, Mah-Jabeen Soobader, Jun Wang, Sibel Blau, Ray D Page,

PURPOSE:Value-based care infers care that is high quality at a comparatively low total cost. A key strategy for value-based oncology care is to avoid unnecessary emergency room (ER) visits and associated hospitalizations of patients receiving treatment for cancer. Early experience with this strategy showed that symptom management in patients with ... Read more >>

J Oncol Pract (Journal of oncology practice)
[2019, 15(2):e91-e97]

Cited: 0 times

View full text PDF listing >>



Impact on Oncology Practices of Including Drug Costs in Bundled Payments.

Jeffery C Ward, Laura A Levit, Ray D Page, John E Hennessy, John V Cox, Deborah Y Kamin, Suanna S Bruinooge, Ya-Chen Tina Shih, Blase N Polite,

INTRODUCTION:This analysis evaluates the impact of bundling drug costs into a hypothetic bundled payment. METHODS:An economic model was created for patient vignettes from: advanced-stage III colon cancer and metastatic non-small-cell lung cancer. First quarter 2016 Medicare reimbursement rates were used to calculate the average fee-for-service (FFS) reimbursement for these vignettes. ... Read more >>

J Oncol Pract (Journal of oncology practice)
[2018, 14(5):e259-e268]

Cited: 3 times

View full text PDF listing >>



Financial Conflicts of Interest Among Oncology Clinical Pathway Vendors.

Bobby Daly, Peter B Bach, Ray D Page,

JAMA Oncol (JAMA oncology)
[2018, 4(2):255-257]

Cited: 1 time

View full text PDF listing >>



Oncology Clinical Pathways: Charting the Landscape of Pathway Providers.

Bobby Daly, Robin T Zon, Ray D Page, Stephen B Edge, Gary H Lyman, Sybil R Green, Dana S Wollins, Linda D Bosserman,

J Oncol Pract (Journal of oncology practice)
[2018, 14(3):e194-e200]

Cited: 2 times

View full text PDF listing >>



nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy.

Michael Thomas, David R Spigel, Robert M Jotte, Michael McCleod, Mark A Socinski, Ray D Page, Laurent Gressot, Jeanna Knoble, Oscar Juan, Daniel Morgensztern, Dolores Isla, Edward S Kim, Howard West, Amy Ko, Teng Jin Ong, Nataliya Trunova, Cesare Gridelli,

Longitudinal data on the impact of treatment on quality of life (QoL) in advanced non-small cell lung cancer (NSCLC) are limited. In this palliative setting, treatment that does not deteriorate QoL is key. Here we report longitudinal QoL in patients with squamous NSCLC, receiving ≤4 cycles of nab-paclitaxel/carboplatin combination chemotherapy.Patients ... Read more >>

Lung Cancer (Auckl) (Lung Cancer (Auckland, N.Z.))
[2017, 8:207-216]

Cited: 2 times

View full text PDF listing >>



The Role of Proteomic Testing in Improving Prognosis And Care Planning Quality Measures for Lung Cancer.

Ray D Page, A Christine Argento, David B Nash, Alexandria Skoufalos, Eric S Schaefer,

The Oncology Care Model (OCM) is a payment model from the Centers for Medicare and Medicaid Services designed to reduce costs and improve quality in cancer care. Key components of quality for the OCM originate from the 13-component cancer care plan. We surveyed the literature to understand the value of ... Read more >>

Manag Care (Managed care (Langhorne, Pa.))
[2017, 26(9):37-47]

Cited: 0 times

View full text PDF listing >>



Impact of a multivariate serum-based proteomic test on physician treatment recommendations for advanced non-small-cell lung cancer.

Wallace L Akerley, Alix M Arnaud, Bibas Reddy, Ray D Page,

The VeriStrat 1 (VS) test is intended to help guide treatment decisions for patients with advanced non-small-cell lung cancer (NSCLC) without an EGFR-sensitizing mutation, classifying patients into two categories. Patients classified as VSGood have a favorable prognosis and significant clinical response to EGFR tyrosine kinase inhibitors (TKIs). Patients classified as ... Read more >>

Curr Med Res Opin (Current medical research and opinion)
[2017, 33(6):1091-1097]

Cited: 3 times

View full text PDF listing >>



American Society of Clinical Oncology Criteria for High-Quality Clinical Pathways in Oncology.

Robin T Zon, Stephen B Edge, Ray D Page, James N Frame, Gary H Lyman, James L Omel, Dana S Wollins, Sybil R Green, Linda D Bosserman,

J Oncol Pract (Journal of oncology practice)
[2017, 13(3):207-210]

Cited: 6 times

View full text PDF listing >>



Oncology Pathways-Preventing a Good Idea From Going Bad.

Blase N Polite, Ray D Page, Chadi Nabhan,

JAMA Oncol (JAMA oncology)
[2016, 2(3):297-298]

Cited: 4 times

View full text PDF listing >>



American Society of Clinical Oncology Policy Statement on Clinical Pathways in Oncology.

Robin T Zon, James N Frame, Michael N Neuss, Ray D Page, Dana S Wollins, Steven Stranne, Linda D Bosserman,

The use of clinical pathways in oncology care is increasingly important to patients and oncology providers as a tool for enhancing both quality and value. However, with increasing adoption of pathways into oncology practice, concerns have been raised by ASCO members and other stakeholders. These include the process being used ... Read more >>

J Oncol Pract (Journal of oncology practice)
[2016, 12(3):261-266]

Cited: 22 times

View full text PDF listing >>



Refining the Standard of Care: How Oncology Treatment Pathways Can Make a Difference.

Ray D Page,

J Oncol Pract (Journal of oncology practice)
[2016, 12(2):143-144]

Cited: 1 time

View full text PDF listing >>



Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: extended analysis of the PROSE trial.

John Hornberger, Fred R Hirsch, Qianyi Li, Ray D Page,

Lung cancer accounts for a significant number of new cancer cases and deaths, with the majority of patients presenting with non-small cell lung cancer (NSCLC). Although epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors are recommended as an alternative to chemotherapy for certain patients, challenges exist for clinical utilization. The objective ... Read more >>

Lung Cancer (Lung cancer (Amsterdam, Netherlands))
[2015, 88(2):223-230]

Cited: 4 times

View full text PDF listing >>



Reply to a. Small et al.

Lee N Newcomer, Sheila A Donelan, Monica Perkins, Bruce Gould, Ray D Page,

J Oncol Pract (Journal of oncology practice)
[2015, 11(2):162]

Cited: 0 times

View full text PDF listing >>



The patient-centered medical home in oncology: from concept to reality.

Ray D Page, Lee N Newcomer, John D Sprandio, Barbara L McAneny,

In recent years, the cost of providing quality cancer care has been subject to an epic escalation causing concerns on the verge of a health care crisis. Innovative patient-management models in oncology based on patient-centered medical home (PCMH) principles, coupled with alternative payments to traditional fee for service (FFS), such ... Read more >>

Am Soc Clin Oncol Educ Book (American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting)
[2015, :e82-9]

Cited: 9 times

View full text PDF listing >>



Payment for oncolytics in the United States: a history of buy and bill and proposals for reform.

Blase N Polite, Jeffery C Ward, John V Cox, Roscoe F Morton, John Hennessy, Ray D Page, Rena M Conti,

J Oncol Pract (Journal of oncology practice)
[2014, 10(6):357-362]

Cited: 8 times

View full text PDF listing >>



Changing physician incentives for affordable, quality cancer care: results of an episode payment model.

Lee N Newcomer, Bruce Gould, Ray D Page, Sheila A Donelan, Monica Perkins,

This study tested the combination of an episode payment coupled with actionable use and quality data as an incentive to improve quality and reduce costs.Medical oncologists were paid a single fee, in lieu of any drug margin, to treat their patients. Chemotherapy medications were reimbursed at the average sales price, ... Read more >>

J Oncol Pract (Journal of oncology practice)
[2014, 10(5):322-326]

Cited: 59 times

View full text PDF listing >>



Patient-reported neuropathy and taxane-associated symptoms in a phase 3 trial of nab-paclitaxel plus carboplatin versus solvent-based paclitaxel plus carboplatin for advanced non-small-cell lung cancer.

Vera Hirsh, Isamu Okamoto, Jeremy K Hon, Ray D Page, James Orsini, Hiroshi Sakai, Hui Zhang, Markus F Renschler, Mark A Socinski,

nab-Paclitaxel (nab-P) is approved, in the United States, in combination with carboplatin for the first-line treatment of advanced non-small-cell lung cancer, based on a randomized phase 3 trial of nab-P plus carboplatin (nab-P/C) versus solvent-based paclitaxel plus carboplatin (sb-P/C). This trial revealed a higher overall response rate (33% versus 25%; ... Read more >>

J Thorac Oncol (Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer)
[2014, 9(1):83-90]

Cited: 16 times

View full text PDF listing >>



Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer.

Radj Gervais, John D Hainsworth, Normand Blais, Benjamin Besse, Janessa Laskin, John T Hamm, Allan Lipton, Kathy S Albain, Gregory A Masters, Ronald B Natale, Paulina Selaru, Sindy T Kim, Richard C Chao, Ray D Page,

This open-label, phase II study evaluated the antitumor activity and safety of sunitinib monotherapy as maintenance treatment following first-line chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Following treatment with standard doublet chemotherapy (paclitaxel and carboplatin), patients received oral sunitinib (starting dose 50mg/day) in 6-week ... Read more >>

Lung Cancer (Lung cancer (Amsterdam, Netherlands))
[2011, 74(3):474-480]

Cited: 13 times

View full text PDF listing >>



Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.

Bertrand Coiffier, Evgenii A Osmanov, Xiaonan Hong, Adriana Scheliga, Jiri Mayer, Fritz Offner, Simon Rule, Adriana Teixeira, Jan Walewski, Sven de Vos, Michael Crump, Ofer Shpilberg, Dixie-Lee Esseltine, Eugene Zhu, Christopher Enny, Panteli Theocharous, Helgi van de Velde, Yusri A Elsayed, Pier Luigi Zinzani, ,

BACKGROUND: Bortezomib and rituximab have shown additive activity in preclinical models of lymphoma, and have been shown to be active and generally well tolerated in a randomised phase 2 study in patients with follicular and marginal zone lymphoma. We compared the efficacy and safety of rituximab alone or combined with ... Read more >>

Lancet Oncol. (The Lancet. Oncology)
[2011, 12(8):773-784]

Cited: 55 times

View full text PDF listing >>



Dose-dense vinorelbine and docetaxel with Filgrastim support in patients with advanced nonsmall cell lung carcinoma.

Ray D Page, Frederick P Smith, George F Geils, Charles L Beall, Moshe Fridman, Barbara J Allen,

BACKGROUND: Vinorelbine and docetaxel are active single agents in the treatment of nonsmall cell lung carcinoma (NSCLC) and may provide enhanced activity when combined in a dose-dense fashion. The efficacy and safety of this combination was assessed when it was administered every 14 days with Filgrastim support in a community ... Read more >>

Cancer (Cancer)
[2005, 104(9):1956-1961]

Cited: 4 times

View full text PDF listing >>





Advertisement

Disclaimer
1.5043 s